U.S. Continuous Renal Replacement Therapy (CRRT) Market Size, Share & Industry Analysis, By Product Type (Systems and Consumables {Dialysates, Replacement Solutions, Filters, Catheters, and Others}), By Modality (Slow Continuous Ultra Filtration {SCUF}, Continuous Venovenous Hemofiltration {CVVH}, Continuous Venovenous Hemodialysis {CVVHD}, and Continuous Venovenous Hemodiafiltration {CVVHDF}), and Country Forecast, 2024-2032

The U.S. continuous renal replacement therapy (CRRT) market size was worth USD 408.1 million in 2023 and is projected to grow at a CAGR of 8.1% during the forecast period.

Continuous renal replacement therapy (CRRT) is a treatment given to severely ill patients admitted to ICUs who are hemodynamically unstable. The increasing incidence of patients admitted to ICU suffering from acute kidney injuries plays an important role in propelling the demand for these systems and consumables.

Additionally, sepsis also affects kidney function in individuals, resulting in the requirement for renal replacement therapy. Thus, a high incidence of sepsis is also expected to supplement the demand for continuous renal replacement therapy (CRRT) products. For instance, as per the CDC data, the number of adult individuals developing sepsis in the U.S. is around 1.7 million.

On the other hand, the COVID-19 pandemic resulted in a positive impact on the market with an increased use of CRRT among U.S. patients. According to a study published in 2020, several U.S. states were projected to witness a shortage of these products due to increased demand during the pandemic.

U.S. Continuous Renal Replacement Therapy (CRRT) Market Trends

Growing Emphasis on the Development of Innovative Products to Propel Market Growth

In recent years, continuous renal replacement therapy (CRRT) products have witnessed an exponential increase in demand for the management of acute kidney diseases. However, the adoption of this technique for the treatment of pediatric AKI patients is comparatively less, which created growth opportunities for market players.

To capture this opportunity, market players have shifted their focus on the development of innovative products. This trend is expected to continue in the coming years as various technological advancements occur in the market.

U.S. Continuous Renal Replacement Therapy (CRRT) Market Growth Factors

Growing ICU Admissions in the U.S. to Propel Market Growth

One of the significant factors driving the market is the increasing number of patients with acute kidney injury admitted to intensive care units in the U.S. hospitals. Furthermore, increased ICU admissions during the COVID-19 pandemic also supported market growth as continuous renal replacement therapy played a crucial role in managing the health of critically ill COVID-19 patients.

Thus, with the increasing prevalence of acute kidney injury among ICU patients and the geriatric population, the technique is considered to be the most preferred therapy for ICU patients owing to their hemodynamic instability. The confluence of all the above-mentioned factors is anticipated to propel the market growth throughout the forecast period.

According to the U.S. Renal Data System Annual Report 2023, in 2020, the hospitalization rate due to AKI decreased majorly due to the changes in overall hospitalization rate due to the COVID-19 pandemic.

RESTRAINING FACTORS

High Upfront Cost Compared to Other Renal Replacement Therapies to Impede Growth Prospects

One of the key factors restraining the U.S. continuous renal replacement therapy (CRRT) market growth is the high upfront cost of the systems compared to other renal replacement therapies. This may hinder the market growth to a certain extent.

According to the Baxter Critical Care Institute, the average base cost of CRRT treatment in the U.S. was USD 39,448. This cost was higher as compared to intermittent hemodialysis (IHD). The difference in cost was majorly due to some patients requiring long-term dialysis.

U.S. Continuous Renal Replacement Therapy (CRRT) Market Segmentation Analysis

By Type Analysis

Based on product type, the market is bifurcated into systems and consumables.

The consumables segment held the dominating position in the market in 2022. Consumables include dialysates, replacement solutions, filters, catheters, and others. Key factors supporting the segment’s dominance include low prices coupled with repeated purchases of these products as per the patients’ requirements.

On the other hand, the systems segment would exhibit considerable growth over the forecast period. This can be attributed to the increasing product launches and advancements in technologies for continuous renal replacement therapy (CRRT).

By Modality Analysis

Based on modality, the market is segmented into Slow Continuous Ultra-Filtration {SCUF}, Continuous Venovenous Hemofiltration {CVVH}, Continuous Venovenous Hemodialysis {CVVHD}, and Continuous Venovenous Hemodiafiltration {CVVHDF}.

In 2022, the Continuous Venovenous Hemodiafiltration (CVVHDF) segment captured the dominating U.S. continuous renal replacement therapy (CRRT) market share. This can be attributed to the fact that this therapy provides clearance over a broad range of solutes with the combination of diffusion and convection techniques. Additionally, according to various sources, CVVHDF is considered the preferred modality in the U.S.

Whereas, the Continuous Venovenous Hemofiltration (CVVH) segment is estimated to grow significantly during the forecast period. CVVH is a necessary alternative in continuous renal replacement therapy (CRRT) if the patient has low blood pressure or other contra indicators to hemodialysis.

List of Key Companies in U.S. Continuous Renal Replacement Therapy (CRRT) Market

The competitive landscape for the U.S. continuous renal replacement therapy (CRRT) market reflects a consolidated structure. Leading players, such as Fresenius Medical Care, Baxter, and B Braun SE, dominate the market with a significant share of the overall market. These companies are adopting various strategies such as collaborations & partnerships, acquisition of small players to expand their market presence, new product launches, and others to maintain their market dominance.

• For instance, in December 2021, to expand its market presence Baxter acquired U.S.-based medical technology and device company Hill-Rom Holdings, Inc.

Some other prominent entities operating in the market include Medtronic, BD, Medical Components Inc., and others. These companies are focusing on expanding their product portfolio to enhance their market presence.

LIST OF KEY COMPANIES PROFILED:

• Baxter (U.S.)


• B Braun SE (Germany)


• Fresenius Medical Care (Fresenius Medical Care AG & Co. KGaA) (Germany)


• Medtronic (Ireland)


• BD (U.S.)


• Medical Components, Inc. (U.S.)


• Asahi Kasei Corporation (Japan)

KEY INDUSTRY DEVELOPMENTS:

• August 2023 – Quanta Dialysis Technologies received the U.S. FDA approval for its Quanta Dialysis System. This approval expanded the use of the system to include CRRT and SCUF modalities.


• December 2020 – Medtronic introduced the Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine for pediatric and neonatal patients.

REPORT COVERAGE

The U.S. continuous renal replacement therapy (CRRT) market report provides a detailed analysis of the market. It focuses on key market segments, such as product type, and modality. Additionally, it includes detailed insights on market dynamics, new product launches, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market for continuous renal replacement therapy (CRRT). Besides this, the report also offers insights into reimbursement scenarios for the U.S. The report also provides the competitive landscape of the key companies at the U.S. level.

Report Scope & Segmentation